US Capitol Capsule: Driving 'bad guys' out: A burden for industry, not taxpayers
This article was originally published in Scrip
With the US trying, and failing, since 1988 to put an efficient national track-and-trace system in place to protect the biopharmaceutical supply chain against counterfeit products and so-called gray marketeers, 2013 could be the year it finally gets underway, with the House already adopting legislation and the Senate set to take up its bill in the coming weeks.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.